Urologists from Cleveland Clinic recently collaborated across borders to perform the world’s first remotely conducted robot–assisted high-intensity focused ultrasound (HIFU) focal therapy procedure ...

In the following interview, co-author and panel member Benjamin M. Brucker, MD, provides a detailed walkthrough of these guidelines and discusses their practical implications for clinicians.He ...

"At the end of the day, it's going to be unlikely that we're going to use a single therapy for all of our patients," says Vignesh T. Packiam, MD. There has been an explosion of treatment options in ...

Discrepancies between the 2 training pathways extend beyond residency, with differences in both practice patterns and physician demographics. Research across various specialties and with diverse ...

64 Cu-SAR-Bombesin works by targeting the gastrin-releasing peptide receptor (GRPR), which is expressed in several malignancies, including prostate cancer, the company noted. "The SABRE trial ...

Panelists discuss how leveraging resources such as patient assistance programs, insurance navigators, clinical trial databases, advocacy groups, and oncology support services can help overcome access ...

In a recent interview, Rebecca A. Campbell, MD, a urologic oncology fellow at Cleveland Clinic in Cleveland, Ohio, discussed concrete steps to mitigate gender-based disparities in Altmetric Attention ...

Physician Summary: Reflections on Progress and Looking Ahead in NMIBC – AUA 2025. As we reflect on the progress made in the treatment of non–muscle-invasive bladder cancer (NMIBC) leading up to AUA ...

In a recent interview, Stacy Loeb, MD, MSc, PhD (Hon), a professor in the departments of urology and population health at NYU Grossman School of Medicine and Perlmutter Cancer Center in New York, New ...

On May 22, 2025, Urology Times ® hosted a Clinical Forum program in Carmel, Indiana. At the event, experts convened to explore the evolving treatment landscape for non–muscle invasive bladder cancer ...

The treatment landscape in benign prostatic hyperplasia (BPH) is shifting toward more personalized approaches to care, according to Dean Elterman, MD, MSc, of the University of Toronto.. In a recent ...

Panelists discuss how the ZIRCON trial demonstrated high positive predictive value (> 90%) for identifying clear cell renal cell carcinoma using a new molecular imaging agent, though negative ...